# Alpha 1-Antitrypsin Deficiency FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/alpha-1-antitrypsin-deficiency

> 2 upcoming FDA catalysts in alpha 1-Antitrypsin Deficiency: alpha-1 15% (GRFS) on Sep to Dec 2027 (topline data readout); alpha-1 15% (GRFS) on September 2027 (primary completion).

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| February 19, 2026 | [Alpha 1-antitrypsin primary completion](https://sec-api.dev/pdufa/alpha-1-antitrypsin) | KMDA | Alpha 1-Antitrypsin Deficiency | withdrawn | "NCT04204252 (Phase III, Efficacy and Safety of "Kamada-AAT for Inhalation"): Overall Status TERMINATED; Phase PHASE3; Primary Completion 2026-02-19 (ACTUAL); Lead Sponsor Kamada, Ltd.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04204252)) |
| Sep to Dec 2027 | [Alpha-1 15% topline data readout](https://sec-api.dev/pdufa/alpha-1-15) | GRFS | Alpha 1 Antitrypsin Deficiency | scheduled | "NCT07555483 (A Non-inferiority Pharmacokinetic and Safety/Tolerability Study of Two Different Doses of Weekly SC Alpha1-PI 15% Compared With Corresponding Standard IV Alpha1-PI in Participants With Alpha1-Antitrypsin Deficiency (AATD)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-09-30 (ESTIMATED); Lead Sponsor Grifols Therapeutics LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07555483)) |
| September 2027 | [Alpha-1 15% primary completion](https://sec-api.dev/pdufa/alpha-1-15) | GRFS | Alpha 1 Antitrypsin Deficiency | scheduled | "NCT07555483 (A Non-inferiority Pharmacokinetic and Safety/Tolerability Study of Two Different Doses of Weekly SC Alpha1-PI 15% Compared With Corresponding Standard IV Alpha1-PI in Participants With Alpha1-Antitrypsin Deficiency (AATD)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-09-30 (ESTIMATED); Lead Sponsor Grifols Therapeutics LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07555483)) |

## Drugs

- [Alpha 1-antitrypsin](https://sec-api.dev/pdufa/alpha-1-antitrypsin) (KMDA)
- [Alpha-1 15%](https://sec-api.dev/pdufa/alpha-1-15) (GRFS)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/alpha-1-antitrypsin-deficiency.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Alpha 1-Antitrypsin Deficiency FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/alpha-1-antitrypsin-deficiency

```bibtex
@misc{secapidev_indications_alpha_1_antitrypsin_deficiency_20261116,
  title        = {Alpha 1-Antitrypsin Deficiency FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/alpha-1-antitrypsin-deficiency}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_alpha_1_antitrypsin_deficiency_20261116","title":"Alpha 1-Antitrypsin Deficiency FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/alpha-1-antitrypsin-deficiency","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
